Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line HIV treatment trial of lopinavir/ritonavir + raltegravir versus lopinavir/ritonavir + NRTIs
ACTRN12609000881235Phase 4Active, not recruiting
- Sponsor
- University of New South Wales
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 4, randomised, open-label trial in Human immunodeficiency virus infection type 1 comparing Lopinavir/ritonavir + 2-3 NRTIs with Lopinavir/ritonavir + raltegravir (2 arms). Primary endpoint: Proportion with HIV RNA <200 copies/mL at 48 and 96 weeks. Started Nov 2009; status: active, not recruiting.
02
Drugs
lopinavir + ritonavirraltegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ACTRN12609000881235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000881235.